4 Analysts Assess Insulet: What You Need To Know

Loading...
Loading...

During the last three months, 4 analysts shared their evaluations of Insulet PODD, revealing diverse outlooks from bullish to bearish.

The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.

Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish
Total Ratings 0 3 1 0 0
Last 30D 0 1 0 0 0
1M Ago 0 0 0 0 0
2M Ago 0 0 0 0 0
3M Ago 0 2 1 0 0

In the assessment of 12-month price targets, analysts unveil insights for Insulet, presenting an average target of $217.0, a high estimate of $230.00, and a low estimate of $200.00. A negative shift in sentiment is evident as analysts have decreased the average price target by 0.46%.

Understanding Analyst Ratings: A Comprehensive Breakdown

The perception of Insulet by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.

Analyst Analyst Firm Action Taken Rating Current Price Target Prior Price Target
Mike Polark Wolfe Research Announces Outperform $200.00 -
Matt Miksic Barclays Lowers Equal-Weight $213.00 $214.00
Matt O'Brien Piper Sandler Lowers Overweight $230.00 $250.00
Robbie Marcus JP Morgan Raises Overweight $225.00 $190.00

Key Insights:

  • Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Insulet. This information provides a snapshot of how analysts perceive the current state of the company.
  • Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Insulet compared to the broader market.
  • Price Targets: Analysts provide insights into price targets, offering estimates for the future value of Insulet's stock. This comparison reveals trends in analysts' expectations over time.

Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Insulet's market position. Stay informed and make well-informed decisions with our Ratings Table.

Stay up to date on Insulet analyst ratings.

Discovering Insulet: A Closer Look

Insulet was founded in 2000 with the goal of making continuous subcutaneous insulin infusion therapy for diabetes easier to use. The result was the Omnipod system, which consists of a small disposable insulin infusion device and that can be operated through a smartphone to control dosage. Since the Omnipod was approved by the U.S. Food and Drug Administration in 2005, approximately 425,000 insulin-dependent diabetics are using it worldwide.

Insulet's Economic Impact: An Analysis

Market Capitalization Perspectives: The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.

Revenue Growth: Insulet displayed positive results in 3 months. As of 31 December, 2023, the company achieved a solid revenue growth rate of approximately 37.9%. This indicates a notable increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Health Care sector.

Net Margin: Insulet's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 20.26%, the company showcases strong profitability and effective cost management.

Return on Equity (ROE): Insulet's ROE excels beyond industry benchmarks, reaching 15.42%. This signifies robust financial management and efficient use of shareholder equity capital.

Return on Assets (ROA): Insulet's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 4.09%, the company showcases efficient use of assets and strong financial health.

Debt Management: Insulet's debt-to-equity ratio surpasses industry norms, standing at 1.93. This suggests the company carries a substantial amount of debt, posing potential financial challenges.

How Are Analyst Ratings Determined?

Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.

Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.

This article was generated by Benzinga's automated content engine and reviewed by an editor.

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
date
ticker
name
Price Target
Upside/Downside
Recommendation
Firm
Posted In: Analyst RatingsBZI-AAR
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...